SEARCH:   Advanced

Blood, 15 November 2003, Vol. 102, No. 10, pp. 3829-3836. Prepublished online as a Blood First Edition Paper on July 24, 2003; DOI 10.1182/blood-2003-04-1022. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-04-1022v1 102/10/3829    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ueno, N. T. Articles by Champlin, R. E. Search for Related Content PubMed PubMed Citation Articles by Ueno, N. T. Articles by Champlin, R. E. Related Collections Immunobiology Neoplasia Transplantation Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors Naoto T. Ueno, Yee Chung Cheng, Gabriela Rondón, Nizar M. Tannir, James L. Gajewski, Daniel R. Couriel, Chitra Hosing, Marcos J. de Lima, Paolo Anderlini, Issa F. Khouri, Daniel J. Booser, Gabriel N. Hortobagyi, Lance C. Pagliaro, Eric Jonasch, Sergio A. Giralt, and Richard E. Champlin From the Departments of Blood and Marrow Transplantation, Breast Cancer Research Program, Breast Medical Oncology, and Genitourinary Medical Oncology, the University of Texas M. D. Anderson Cancer Center, Houston. We evaluated the feasibility and efficacy of a reduced-intensity conditioning (RIC) regimen of fludarabine and melphalan to achieve rapid complete donor chimerism after allogeneic stem cell transplantation (SCT) in patients with metastatic solid tumors. Between January 1999 and January 2003, 8 patients with metastatic breast cancer (BC) and 15 with metastatic renal cell carcinoma (RCC) underwent allogeneic SCT after an RIC regimen of 5 days of fludarabine and 2 days of melphalan. Filgrastim-mobilized stem cells from HLA-identical related or unrelated donors were infused. Prophylaxis for graft-versus-host disease (GVHD) consisted of tacrolimus and methotrexate. All 22 evaluable patients had 100% donor chimerism at day 30 and at all measurement times thereafter. One patient died 19 days after SCT. Nine patients (39%) had grades II to IV acute GVHD and 10 patients (43%) had chronic GVHD. Five patients (22%) died of nonrelapse treatment-related complications. Treatment-related disease response was seen in 10 patients (45%), with 3 complete responses, 2 partial responses, and 5 minor responses. Fludarabine-melphalan is a feasible and effective RIC regimen for allogeneic SCT in metastatic BC and RCC. It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect. (Blood. 2003;102:3829-3836) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Eto, Y. Kamiryo, A. Takeuchi, M. Harano, K. Tatsugami, M. Harada, K. Kiyoshima, M. Hamaguchi, T. Teshima, M. Tsuneyoshi, et al. Posttransplant Administration of Cyclophosphamide and Donor Lymphocyte Infusion Induces Potent Antitumor Immunity to Solid Tumor Clin. Cancer Res., May 1, 2008; 14(9): 2833 - 2840. [Abstract] [Full Text] [PDF] R. Conrad, M. Remberger, K. Cederlund, O. Ringden, and L. Barkholt A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors Haematologica, February 1, 2008; 93(2): 265 - 272. [Abstract] [Full Text] [PDF] A. M. Carella, R. Ferrara, G. F. Orcioni, G. Pepe, and G. Villavecchia Profound graft-versus-tumor response in metastatic breast cancer with nonmyeloablative allografting Ann. Onc., October 1, 2007; 18(10): 1751 - 1754. [Full Text] [PDF] A. M. Carella and M. Bregni Current role of allogeneic stem cell transplantation in breast cancer Ann. Onc., October 1, 2007; 18(10): 1591 - 1593. [Full Text] [PDF] M. Eto, M. Harano, K. Tatsugami, M. Harada, Y. Kamiryo, K. Kiyoshima, M. Hamaguchi, M. Tsuneyoshi, Y. Yoshikai, and S. Naito Cyclophosphamide-Using Nonmyeloablative Allogeneic Cell Therapy against Renal Cancer with a Reduced Risk of Graft-versus-Host Disease Clin. Cancer Res., February 1, 2007; 13(3): 1029 - 1035. [Abstract] [Full Text] [PDF] J. C. Yang and R. Childs Immunotherapy for Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5576 - 5583. [Abstract] [Full Text] [PDF] F. Carnevale-Schianca, A. Cignetti, A. Capaldi, K. Vitaggio, A. Vallario, A. Ricchiardi, E. Sperti, R. Ferraris, M. Gatti, G. Grignani, et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD Blood, May 1, 2006; 107(9): 3795 - 3803. [Abstract] [Full Text] [PDF] M. Ohashi, A. Kobayashi, H. Hara, Y. Miura, K. Yoshida, M. Kushida, Y. Ikarashi, M. Mandai, M. Kitajima, T. Yoshida, et al. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2208 - 2215. [Abstract] [Full Text] [PDF] M. Harano, M. Eto, T. Iwai, K. Tatsugami, K. Kiyoshima, Y. Kamiryo, M. Tsuneyoshi, Y. Yoshikai, and S. Naito Renal Cancer Treatment with Low Levels of Mixed Chimerism Induced by Nonmyeloablative Regimen Using Cyclophosphamide in Mice Cancer Res., November 1, 2005; 65(21): 10032 - 10040. [Abstract] [Full Text] [PDF] S. S. Tykodi, E. H. Warren, J. A. Thompson, S. R. Riddell, R. W. Childs, B. E. Otterud, M. F. Leppert, R. Storb, and B. M. Sandmaier Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens Clin. Cancer Res., December 1, 2004; 10(23): 7799 - 7811. [Abstract] [Full Text] [PDF] A. Dorrschuck, A. Schmidt, E. Schnurer, M. Gluckmann, C. Albrecht, C. Wolfel, V. Lennerz, A. Lifke, C. Di Natale, E. Ranieri, et al. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression Blood, October 15, 2004; 104(8): 2591 - 2599. [Abstract] [Full Text] [PDF] N. T. Ueno, E. J. Shpall, R. E. Champlin, and R. B. Jones Graft--Versus--Breast Cancer Effect by Allogeneic Hematopoietic Stem-Cell Transplantation: A Possible New Frontier J. Clin. Oncol., October 1, 2004; 22(19): 3846 - 3847. [Full Text] [PDF] Y. Takahashi and R. W. Childs Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6353S - 6359S. [Abstract] [Full Text] [PDF] A. Nencioni and P. Brossart Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status Stem Cells, July 1, 2004; 22(4): 501 - 513. [Abstract] [Full Text] [PDF] T. Igarashi, J. Wynberg, R. Srinivasan, B. Becknell, J. P. McCoy Jr, Y. Takahashi, D. A. Suffredini, W. M. Linehan, M. A. Caligiuri, and R. W. Childs Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells Blood, July 1, 2004; 104(1): 170 - 177. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020